Sepetaprost

Drug Profile

Sepetaprost

Alternative Names: DE 126; ONO 9054

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 31 Aug 2016 Phase-II development is ongoing in USA
  • 30 Mar 2016 Sepetoprost licensed to Santen Pharmaceuticals worldwide for the treatment of Open angle glaucoma and Ocular hypertension
  • 01 Dec 2014 Ono Pharmaceutical completes a phase II trial for Ocular hypertension and Open angle glaucoma in USA (NCT02083289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top